TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05700032

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: high MI impulses
Description: patients will receive intermittent high MI impulses(\>1.0) in addition to low MI imaging. LVOT VTI will be measured at different times per protocol.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: low MI impulses
Description: patients will receive low MI imaging only. LVOT VTI will be measured at different times per protocol.
Study: NCT05676216

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diphenhydramine
Description: Diphenhydramine 30 mg in 100 mL normal saline intravenous dripping when vertigo patients visit Emergency Department
Study: NCT05978063

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: difelikefalin 1.0 mg tablets
Description: Oral difelikefalin 1.0 mg administered twice daily
Study: NCT05676216

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Bicarbonate
Description: Sodium bicarbonate 66.4 mEq in 100 mL normal saline intravenous dripping when vertigo patients visit Emergency Department
Study: NCT05612685

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthcare provider referral to a tax filing app
Description: Healthcare providers offer a referral to a tax filing app and briefly describe the potential benefits of tax credit receipt
Study: NCT05445765

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-CD33 CAR T cells
Description: Anti-CD33 CAR T cells are used to treat patients. Patient will be administered either fresh or thawed CAR T cells by IV injection after receiving lymphodepleting chemotherapy.
Study: NCT05836207

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Abstinence-focused Contingency Management (CM) - stand alone
Description: Outpatient abstinence-focused contingency management (CM) as stand-alone treatment (12 weeks). Monetary incentives (vouchers) are provided for cannabis abstinence, based on twice-weekly rapid test urinalysis and an escalating reward scheme with bonuses. Urine samples are collected at the treatment centre during 15-minute sessions by a trained CM-practitioner. For each cannabis-negative urine, patients receive a monetary voucher starting at €5 and escalating to max. €35 after eight consecutive weeks of cannabis abstinence, with an additional €10 bonus after two consecutive cannabis-negative urines. The voucher-value is reset to €5 after a cannabis-positive urine test. Total earnings can be max. €675 for 12 weeks of consecutive cannabis abstinence (average: €8 p/day). Youths sign an agreement stating that vouchers must be spent on recovery-oriented goals.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Outpatient Cognitive Behavioural Therapy (CBT)
Description: CBT is the usual care first line treatment for CUD in youth, in the Netherlands. CBT for CUD is focused on learning cognitive, emotional, motivational and behavioral skills to reduce or cease cannabis use, and generally consists of 12 once-weekly 60-minute sessions and 'homework' exercise assignments, provided by a psychologist.~Youths receive 12 weeks of outpatient usual care CBT consisting of once-weekly 60-minute sessions according to the standard CBT youth protocol by a trained psychologist. CBT-youths receive the same cannabis urine-testing procedures as CM-youths, but test results will not be disclosed to treatment staff or patient, and no rewards will be given for cannabis abstinence.
Study: NCT05431426

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CH6001
Description: CHF6001 will be administered using the NEXThaler® DPI device
Study: NCT04811170

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Counselling
Description: Participants with mild to moderate mood symptoms will receive a maximum of 6 counselling sessions and will be assessed at baseline (T0, W1), at post-treatment for counselling group (T1, W8), and after 2 booster sessions. Participants in the waiting list control group will receive the same counselling service after the counselling group completed the intervention. Participants with severe mood symptoms will receive a maximum of 10 counselling sessions and will be assessed at baseline (T0, W1), at post-treatment for counselling group (T1, W12), and after 2 booster sessions. Participants in the waiting list control group will receive the same counselling service after the counselling group completed the intervention.

Intervention type: OTHER
Group type: OTHER
Intervention: Counselling
Description: Participants with mild to moderate mood symptoms will receive a maximum of 6 counselling sessions and will be assessed at baseline (T0, W1), at post-treatment for counselling group (T1, W8), and after 2 booster sessions. Participants in the waiting list control group will receive the same counselling service after the counselling group completed the intervention. Participants with severe mood symptoms will receive a maximum of 10 counselling sessions and will be assessed at baseline (T0, W1), at post-treatment for counselling group (T1, W12), and after 2 booster sessions. Participants in the waiting list control group will receive the same counselling service after the counselling group completed the intervention.
Study: NCT05676216

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine + Sodium Bicarbonate
Description: Diphenhydramine 30 mg in 100 mL normal saline intravenous dripping with Sodium bicarbonate 66.4 mEq intravenous push when vertigo patients visit Emergency Department
Study: NCT05431426

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CH6001
Description: CHF6001 will be administered using the NEXThaler® DPI device

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CH6001
Description: CHF6001 will be administered using the NEXThaler® DPI device
Study: NCT05008874

Intervention type: OTHER
Intervention: Natural History Observation
Description: Data collection on progression of disease
Study: NCT05978063

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: difelikefalin 0.25 mg tablets
Description: Oral difelikefalin 0.25 mg administered twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablets
Description: Oral Placebo administered twice daily
Study: NCT04470362

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Isokinetic dynamometer
Description: an isokinetic strengthening program for the quadriceps muscles. Twenty-four strengthening session will be performed using an isokinetic device. The exercise program begins with 60% of the mean peak torque, and the patient reaches this intensity by auditory biofeedback. An increasing dose program will be used in the first 5 sessions (1 set to 5 sets), and a dose of 6 sets will be applied from the sixth to twenty-fourth sessions, with the density rising from 60% to 80% of the mean peak torque according to the patient tolerance. Each set consisted of 5 repetitions of concentric (Con/Ecc) contraction in angular velocities of 30°/second and 120°/second for extensors. This program accomplished significant results in increasing the quadriceps power and strength.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Isokinetic dynamometer
Description: an isokinetic strengthening program for the quadriceps muscles. Twenty-four strengthening session will be performed using an isokinetic device. The exercise program begins with 60% of the mean peak torque, and the patient reaches this intensity by auditory biofeedback. An increasing dose program will be used in the first 5 sessions (1 set to 5 sets), and a dose of 6 sets will be applied from the sixth to twenty-fourth sessions, with the density rising from 60% to 80% of the mean peak torque according to the patient tolerance. Each set consisted of 5 repetitions of concentric (Con/Ecc) contraction in angular velocities of 30°/second and 120°/second for extensors. This program accomplished significant results in increasing the quadriceps power and strength.
Study: NCT05473117

Intervention type: DIAGNOSTIC_TEST
Intervention: Coronary Magnetic Resonance Angiography (CMRA)
Description: A highly optimised CMRA protocol integrating advanced, automated software for detection of coronary artery stenosis
Study: NCT05752370

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High flow oxygen
Description: Use of HFO

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Room air or normal flow oxygen
Study: NCT06259240

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Prone plank exercises
Description: Patients in this group will recieve prone plank exercises, three times a week, for eight weeks, and with a moderate hard intensity. During the first four weeks, the exercises session began with light walking for five minutes followed by corrected exercises. Firstly, women will perform stable prone plank exercises. Secondly, women will be asked to apply the unilateral position of prone plank. Thirdly, using a 65 cm diameter Swiss ball, women will be asked to assume the prone bridge position. During the last four weeks, women will be asked to repeat the same program noting that the progressive prone plank exercises should be applied in a dosage of 20 repetitions, three sets, holding the contraction for one minute, and taking a break for two minutes.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Electrical Stimulation
Description: Electrical Stimulation
Study: NCT05145244

Intervention type: OTHER
Intervention: NO intervention
Description: No intervention

Intervention type: OTHER
Intervention: NO intervention
Description: No intervention
Study: NCT04029298

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Lifestyle Interventions
Description: Educational based intervention to enhance lifestyle modifications such as diet, exercise, patient activation, and medication adherence

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Interventions
Description: Educational based intervention to enhance lifestyle modifications such as diet, exercise, patient activation, and medication adherence
Study: NCT06019377

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stronger Youth Networks and Coping (SYNC)
Description: SYNC is a 10-module online curriculum adapted from evidence-based cognitive change methods, including Coping Effectiveness Training (CET), co-facilitated by service providers in Independent Living Programs (ILPs; federally-funded transition skill-building services accessed by most foster youth in the US) and near-peers (have lived experience in foster care). SYNC aims to increase youth capacity to appraise stress and regulate emotional responses, to flexibly select adaptive coping strategies, and to specifically promote informal and formal help-seeking as an effective coping strategy.
Study: NCT06136065

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 68 Gallium -Fibroblast Activating Protein Inhibitor -46 Positron emission tomography / Computerized tomography
Description: 68 Gallium -Fibroblast Activating Protein Inhibitor -46 Positron emission tomography / Computerized tomography scan
Study: NCT06050785

Intervention type: DRUG
Intervention: Vancomycin
Description: ACL graft will be soaked in vancomycin versus gentamycin

Intervention type: DRUG
Intervention: Vancomycin
Description: ACL graft will be soaked in vancomycin versus gentamycin
Study: NCT05949827

Intervention type: DEVICE
Intervention: Dynamic Light Therapy Device, LSA-1
Description: Dynamic Light Therapy

Intervention type: DEVICE
Intervention: Dynamic Light Therapy Device, LSA-2
Description: Dynamic Light Therapy

Intervention type: DEVICE
Intervention: Dynamic Light Therapy Device, LSA-3
Description: Dynamic Light Therapy
Study: NCT05028270

Intervention type: PROCEDURE
Intervention: Balloon technology;Microcatheter technology
Description: Describe each group's intervention in sufficient detail, including how and when to give the intervention Suspend or modify the criteria for interventions that have been assigned to the subject (such as changing the dose of the drug due to hazards or subject requirements or improvement/deterioration of the condition, etc.) Strategies to improve the compliance of intervention programs, and other measures to monitor compliance (such as the return of drug tablets, laboratory inspections, etc.) Related care and interventions allowed or prohibited during the trial
Study: NCT05647785

Intervention type: DEVICE
Intervention: Long-term follow-up of cerena™
Description: Long term follow-up for eligible participants from the RESTORE study

Intervention type: DEVICE
Intervention: Long-term follow-up of attune™
Description: Long term follow-up for eligible participants from the RESTORE study
Study: NCT06218290

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxylanthanum Carbonate
Description: Phosphate Binder to Reduce Hyperphosphatemia
Study: NCT05551195

Intervention type: DEVICE
Group type: OTHER
Intervention: WB001
Description: WB001 is a digital therapeutic for postpartum depression.

Intervention type: DEVICE
Group type: OTHER
Intervention: ED001
Description: ED001 is a digital therapeutic for postpartum depression.
Study: NCT05286034

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Decision aid tailored to women with lower educational attainment,accessible via artificial intelligence-based Chatbot platforms
Description: Non-compliant women those that have not been screened for more than 4 years and living in the disadvantaged areas will be sent screening reminder letters to perform HPV self-sampling (HPVss) test, with access to decision aid tailored to women with lower education attainment and available via Chatbot platforms.~ChatBot will deliver information in a responsive, conversational way via text and spoken language in multiple languages through multiple mobile channels.
Study: NCT05807685

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: laughter therapy
Description: Description: Laughter therapy session will be applied online for 25-30 minutes once a week for 2 months by the researchers who has the Laughter therapy certificate to the application group. In the laughter therapy session, the practices of introducing the practitioner and introducing the therapy, breathing exercises for a healthy life, keeping the rhythm accompanied by music, turning the laughter that started as if it were childlike games into reality will be carried out.
Study: NCT04717154

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: 4 courses of 1mg/kg q3w

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 4 courses of 3mg/kg q3w, followed by maintenance flat dose (480mg, q4w, for 10 doses)
Study: NCT05186220

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cardioneuroablation
Description: After 3D mapping of the surface of the left and right atrium and the superior vena cava (Ensite Navx, Carto), localization of ganglion plexus (GP) will be performed either anatomically and/or by means of high frequency stimulation (HFS). The anterior and superior right sided GP will always be ablated per protocol. Other GP will be ablated according to interventional electrophysiologist judgement. The endpoint of the ablation procedure will be 1) absence of a vagal response after HFS from the right jugular vein and 2) an increase in at least 10 bpm as compared to baseline.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Permanent dual chamber pacemaker implantation
Description: Under local anesthesia and using a subclavian or cephalic vein approach a dual chamber pacemaker implantation with a lead in the right atrium and a lead in the right ventricle will be performed. The device will be programmed in a AAI-DDDR mode to avoid unnecessary ventricular pacing.
Study: NCT04783077

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WhatsApp
Description: Participants assigned to the WhatsApp group will receive weekly messages developed by communication specialists aimed to motivate blood donation, be encouraged to discuss their blood donation experiences, and share their own motivations for donating blood in a moderated, closed group over a six-month duration. The moderator will provide guidelines on acceptable use of WhatsApp in the group, including images they can or cannot share. Participants will also receive standard NBSG communications for first-time donors.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WhatsApp
Description: Participants assigned to the WhatsApp group will receive weekly messages developed by communication specialists aimed to motivate blood donation, be encouraged to discuss their blood donation experiences, and share their own motivations for donating blood in a moderated, closed group over a six-month duration. The moderator will provide guidelines on acceptable use of WhatsApp in the group, including images they can or cannot share. Participants will also receive standard NBSG communications for first-time donors.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Participants in this group will receive the standard NBSG communications for first-time donors: 1) a thank you phone call and 2) and a reminder phone call two-weeks prior to the second blood donation eligibility. The second blood donation eligibility is four months after the first donation.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Participants in this group will receive the standard NBSG communications for first-time donors: 1) a thank you phone call and 2) and a reminder phone call two-weeks prior to the second blood donation eligibility. The second blood donation eligibility is four months after the first donation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Docudrama
Description: Participants will be exposed to a document-drama related to blood donation.
Study: NCT04830488

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: e-learning didactic module
Description: Participants utilize e-learning

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personal reflection activities
Description: Participants complete questionnaires
Study: NCT05813522

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furmonertinib Mesilate Tablets
Description: 160mg of Furmonertinib mesilate tablets (given as four 40mg tablets) administered orally once daily
Study: NCT05876273

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neural-net Artificial Pancreas
Description: NAP is a neural-net implementation of the previously tested UMPC algorithm (below).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neural-net Artificial Pancreas
Description: NAP is a neural-net implementation of the previously tested UMPC algorithm (below).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: University of Virginia Model Predictive Control
Description: A previously tested artificial pancreas control algorithm, based on a differential-equation model of the human metabolic system in diabetes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: University of Virginia Model Predictive Control
Description: A previously tested artificial pancreas control algorithm, based on a differential-equation model of the human metabolic system in diabetes.
Study: NCT05446883

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QL1706
Description: Intravenous Infusion
Study: NCT05013307

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CASE
Description: The Clinical Assessment for Sports Exertion (CASE) addresses the physical performance of athletes by quantifying physiological and symptomatic responses to dynamic exertion. It was developed by clinicians at the Baylor Scott and White Sports Concussion Program in an effort to identify specific system impairments in athletes who were unable to successfully demonstrate readiness for return to play protocols.
Study: NCT05945160

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpha Lipoic Acid 300mg
Description: A naturally occuring mitochondrial antioxidant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 200mg
Description: A naturally occuring mitochondrial antioxidant
Study: NCT05401318

Intervention type: PROCEDURE
Intervention: Tumor tissue sampling for organoid development
Description: Fresh tissue from colorectal tumors will be sampled and cultivated in 3D cultures for drug testing.
Study: NCT05032885

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physiotherapy
Description: Patients in the intervention group will receive early physiotherapy treatment. This intervention will consist of exercises and physiotherapy techniques commonly used and aimed at improving the patient's respiratory and motor conditioning.~At the respiratory level: diaphragmatic and costal targeted ventilation, pursed-lip breathing and bronchial hygiene techniques if required.~At the motor level: passive, active-assisted kinesitherapy and analytical and global potentiation of the upper and lower limbs that will allow the maintenance and improvement of the articular pathway and will prevent muscle weakness; retraining of transfers and balance; gait reeducation.
Study: NCT05446883

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous Infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel injection
Description: Intravenous Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel injection
Description: Intravenous Infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cisplatin/Carboplatin
Description: Intravenous Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin/Carboplatin
Description: Intravenous Infusion